MedTrace Logo

18F-S16 PET/CT in Healthy Volunteers and Patients With Neurodegenerative Dementia

NCT03620552 · Status: UNKNOWN · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2018-08-08

No results posted yet for this study

Summary

This is an open-label dynamic whole-body PET/CT (positron emission tomography/computed tomography) study for investigation of radiation dosimetry, plasma pharmacokinetics, biodistribution, safety and diagnostic performance of 18F-S16 in healthy volunteers and patients with neurodegenerative dementia.

Conditions

  • Neurodegenerative Dementia

Interventions

DRUG

18F-S16

A single dose of nearly 370MBq 18F-S16 were intravenously injected into the subjects immediately before the PET/CT scans

Sponsors & Collaborators

  • Oriental Neurosurgery Evidence-Based-Study Team

    lead OTHER

Principal Investigators

  • Li Cai, MD · Tianjin Medical University General Hospital

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-08-20
Primary Completion
2018-10-20
Completion
2019-02-20

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620552 on ClinicalTrials.gov